LJ-1888, a selective antagonist for the A3 adenosine receptor, ameliorates the development of atherosclerosis and hypercholesterolemia in apolipoprotein E knock-out mice
0
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Cardiovascular diseases arising from atherosclerosis are the leading causes of mortality and morbidity worldwide. Lipid-lowering agents have been developed in order to treat hypercholesterolemia, a major risk factor for atherosclerosis. However, the prevalence of cardiovascular diseases is increasing, indicating a need to identify novel therapeutic targets and develop new treatment agents. Adenosine receptors (ARs) are emerging as therapeutic targets in asthma, rheumatoid arthritis, cancer, ischemia, and inflammatory diseases. This study assessed whether LJ-1888, a selective antagonist for A3 AR, can inhibit the development of atherosclerosis in apolipoprotein E knock-out (ApoE−/−) mice who are fed a western diet. Plaque formation was significantly lower in ApoE−/− mice administered LJ-1888 than in mice not administered LJ-1888, without any associated liver damage. LJ-1888 treatment of ApoE−/− mice prevented western diet-induced hypercholesterolemia by markedly reducing low-density lipoprotein cholesterol levels and significantly increasing high-density lipoprotein cholesterol concentrations. Reduced hypercholesterolemia in ApoE−/− mice administered LJ-1888 was associated with the enhanced expression of genes involved in bile acid biosynthesis. These findings indicate that LJ-1888, a selective antagonist for A3 AR, may be a novel candidate for the treatment of atherosclerosis and hypercholesterolemia.
Abstract
Cardiovascular diseases arising from atherosclerosis are the leading causes of mortality and morbidity worldwide. Lipid-lowering agents have been developed in order to treat hypercholesterolemia, a major risk factor for atherosclerosis. However, the prevalence of cardiovascular diseases is increasing, indicating a need to identify novel therapeutic targets and develop new treatment agents. Adenosine receptors (ARs) are emerging as therapeutic targets in asthma, rheumatoid arthritis, cancer, ischemia, and inflammatory diseases. This study assessed whether LJ-1888, a selective antagonist for A3 AR, can inhibit the development of atherosclerosis in apolipoprotein E knock-out (ApoE−/−) mice who are fed a western diet. Plaque formation was significantly lower in ApoE−/− mice administered LJ-1888 than in mice not administered LJ-1888, without any associated liver damage. LJ-1888 treatment of ApoE−/− mice prevented western diet-induced hypercholesterolemia by markedly reducing low-density lipoprotein cholesterol levels and significantly increasing high-density lipoprotein cholesterol concentrations. Reduced hypercholesterolemia in ApoE−/− mice administered LJ-1888 was associated with the enhanced expression of genes involved in bile acid biosynthesis. These findings indicate that LJ-1888, a selective antagonist for A3 AR, may be a novel candidate for the treatment of atherosclerosis and hypercholesterolemia.
참고문헌 (41)
- Nelson RH, "Hyperlipidemia as a risk factor for cardiovascular disease", Prim Care, 40, pp.195~211 (2013)[DOI]
- 정세진, "The Role of Macrophage Lipophagy in Reverse Cholesterol Transport", Endocrinology and Metabolism, 32(1), pp.41~46 (2017), 대한내분비학회
- Weber C, "Atherosclerosis: current pathogenesis and therapeutic options", Nat Med, 17, pp.1410~1422 (2011)[DOI]
- Hebert PR, "Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials", Jama, 278, pp.313~321 (1997)[DOI]
- Pignone M, "Use of lipid lowering drugs for primary prevention of coronary heart disease: meta-analysis of randomised trials", BMJ, 321, pp.983~986 (2000)[DOI]
- Cheung BM, "Is intensive LDLcholesterol lowering beneficial and safe?", Lancet, 376, pp.1622~1624 (2010)[DOI]
- Nissen SE, "Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease", N Engl J Med, 352, pp.29~38 (2005)[DOI]
- Davis HR Jr, "Ezetimibe, a potent cholesterol absorption inhibitor, inhibits the development of atherosclerosis in ApoE knockout mice", Arterioscler Thromb Vasc Biol, 21, pp.2032~2038 (2001)[DOI]
- Smith L, "The New Face of Hyperlipidemia Management: Proprotein Convertase Subtilisin", Kexin Inhibitors (PCSK-9) and Their Emergent Role As An Alternative To Statin Therapy, 2016, pp.19, 137~146
- Brousseau ME, "Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol", N Engl J Med, 350, pp.1505~1515 (2004)[DOI]
- White CR, "HDL therapy for cardiovascular diseases: the road to HDL mimetics", Curr Atheroscler Rep, 10, pp.405~412 (2008)[DOI]
- Writing Group M, "Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association", Circulation, 133, pp.e38~e360 (2016)
- Layland J, "Adenosine: physiology, pharmacology, and clinical applications", JACC Cardiovasc Interv, 7, pp.581~591 (2014)[DOI]
- Bowser JL, "The hypoxia-adenosine link during inflammation", J Appl Physiol, 123, pp.1303~1320 (2017)[DOI]
- Sheth S, "Adenosine receptors: expression, function and regulation", Int J Mol Sci, 15, pp.2024~2052 (2014)[DOI]
- Chen JF, "Adenosine receptors as drug targets--what are the challenges?", Nat Rev Drug Discov, 12, pp.265~286 (2013)[DOI]
- Jacobson KA, "Adenosine A3 receptors: novel ligands and paradoxical effects", Trends Pharmacol Sci, 19, pp.184~191 (1998)[DOI]
- Borea PA, "The A3 adenosine receptor: history and perspectives", Pharmacol Rev, 67, pp.74~102 (2015)
- Jeong LS, "Discovery of a new nucleoside template for human A3 adenosine receptor ligands: D-4'-thioadenosine derivatives without 4'-hydroxymethyl group as highly potent and selective antagonists", J Med Chem, 50, pp.3159~3162 (2007)[DOI]
- Lee J, "The selective A3AR antagonist LJ-1888 ameliorates UUO-induced tubulointerstitial fibrosis", Am J Pathol, 183, pp.1488~1497 (2013)[DOI]
- Libby P, "Progress and challenges in translating the biology of atherosclerosis", Nature, 473, pp.317~325 (2011)[DOI]
- Libby P, "Current concepts in cardiovascular pathology: the role of LDL cholesterol in plaque rupture and stabilization", Am J Med, 104, pp.14S~18S (1998)
- Istvan ES, "Structural mechanism for statin inhibition of HMG-CoA reductase", Science, 292, pp.1160~1164 (2001)[DOI]
- Hou R, "Lowering low-density lipoprotein cholesterol: statins, ezetimibe, bile acid sequestrants, and combinations: comparative efficacy and safety", Endocrinol Metab Clin North Am, 38, pp.79~97 (2009)[DOI]
- Lee MR, "The adipokine Retnla modulates cholesterol homeostasis in hyperlipidemic mice", Nat Commun, 5, pp.4410~ (2014)[DOI]
- Chiang JY, "Bile acids: regulation of synthesis", J Lipid Res, 50, pp.1955~1966 (2009)[DOI]
- Chiang JY, "Farnesoid X receptor responds to bile acids and represses cholesterol 7alpha-hydroxylase gene (CYP7A1) transcription", J Biol Chem, 275, pp.10918~10924 (2000)[DOI]
- Bonovas S, "Efficacy and safety of more intensive lowering of LDL cholesterol", Lancet, 377, pp.715~ (2011)
- Tobert JA, "Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors", Nat Rev Drug Discov, 2, pp.517~526 (2003)[DOI]
- Pedersen TR, "Benefits and risks of HMG-CoA reductase inhibitors in the prevention of coronary heart disease: a reappraisal", Drug Saf, 14, pp.11~24 (1996)[DOI]
- Dembowski E, "Statin and ezetimibe combination therapy in cardiovascular disease", Curr Opin Endocrinol Diabetes Obes, 16, pp.183~188 (2009)[DOI]
- Michos ED, "Niacin and statin combination therapy for atherosclerosis regression and prevention of cardiovascular disease events: reconciling the AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL", High Triglycerides: Impact on Global Health Outcomes) trial with previous surrogate endpoint trials, 2012, pp.59, 2058~2064
- Leiva A, "Adenosine receptors: Modulators of lipid availability that are controlled by lipid levels", Mol Aspects Med, 55, pp.26~44 (2017)[DOI]
- Reiss AB, "Regulation of foam cells by adenosine", Arterioscler Thromb Vasc Biol, 32, pp.879~886 (2012)[DOI]
- Ohisalo JJ, "Effects of adenosine on lipolysis in human subcutaneous fat cells", J Clin Endocrinol Metab, 52, pp.359~363 (1981)[DOI]
- Heseltine L, "Adenosine effects upon insulin action on lipolysis and glucose transport in human adipocytes", Mol Cell Biochem, 144, pp.147~151 (1995)[DOI]
- Bingham TC, "A2A adenosine receptor stimulation decreases foam cell formation by enhancing ABCA1-dependent cholesterol efflux", J Leukoc Biol, 87, pp.683~690 (2010)[DOI]
- Jones MR, "A(3) adenosine receptor deficiency does not influence atherogenesis", J Cell Biochem, 92, pp.1034~1043 (2004)[DOI]
- Yu J, "Polypharmacology of N(6)-(3-Iodobenzyl)adenosine-5'-N-methyluronamide (IB-MECA) and Related A3 Adenosine Receptor Ligands: Peroxisome Proliferator Activated Receptor (PPAR) gamma Partial Agonist and PPARdelta Antagonist Activity Suggests Their Antidiabetic Potential", J Med Chem, 60, pp.7459~7475 (2017)[DOI]
- 박현주, "Gastrin-releasing peptide promotes the migration of vascular smooth muscle cells through upregulation of matrix metalloproteinase-2 and -9", BMB Reports, 50(12), pp.628~633 (2017), 생화학분자생물학회
- 정혜진, "Effects of chlorogenic acid on intracellular calcium regulation in lysophosphatidylcholine-treated endothelial cells", BMB Reports, 50(6), pp.323~328 (2017), 생화학분자생물학회